Mangalam Drugs And Organics Limited (MANGALAM)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹27.42 ↓ 68.31% (1Y)

🎯 Key Takeaways

Mangalam Drugs and Organics Limited is in a fragile financial and operational phase, marked by declining profitability and a recent loan default disclosure. The company has experienced a sharp drop in one-year returns (-68.
Revenue grew 11% QoQ to ₹89 in Q3FY25.
⚠️ Liquidity and repayment stress on short-term obligations, as evidenced by the ₹1.56 crore loan default to two public sector banks.

Debt/Equity

0.00

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About MANGALAM 📊 Interactive Charts

📖 The Story

Mangalam Drugs and Organics Limited is in a fragile financial and operational phase, marked by declining profitability and a recent loan default disclosure. The company has experienced a sharp drop in one-year returns (-68.31%), reflecting investor concern over its stability. Despite operating in the pharmaceutical sector, recent financial trends show weakening margins and inconsistent earnings, with no clear growth trajectory evident in the latest quarterly results.

📰 What's Happening

The most material development was the disclosure on May 16, 2026, of a loan default exceeding 30 days to Bank of Baroda and Bank of Maharashtra, with overdue amounts totaling ₹1.56 crore. This was formally communicated to exchanges under SEBI regulations, signaling potential stress in the company's capital structure. Prior to this, the company filed routine general updates on April 21 and June 17, 2026, which contained no operational or financial updates of significance. There is no evidence of new product launches, capacity expansions, or strategic initiatives in recent filings.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	0	97	102	77	80	89
Operating Profit	—	7	12	8	9	9
OPM %	—	7.2%	11.4%	10.7%	10.9%	9.9%
Net Profit	0	1	4	3	3	1
EPS	₹0.00	₹0.31	₹2.23	₹1.70	₹1.70	₹0.81

Quarterly revenue peaked at ₹102 crore in Q4FY24 but has since declined to ₹89 crore in Q3FY25, indicating a downward trend. Operating profit margins have also softened to 9.9% from a high of 11.4% in Q4FY24, while net profit fell sharply from ₹4 crore to ₹1 crore over the same period. EPS declined from ₹2.23 to ₹0.81, reflecting weakening bottom-line performance. These trends suggest that earlier operational momentum has not been sustained, and margin compression is emerging despite stable revenue levels.

🔮 Management Outlook & What's Next

There is no available forward guidance or explicit outlook from management in the latest filings. The company has not issued any earnings projections, capital allocation plans, or strategic updates beyond routine disclosures. The absence of commentary on future performance limits visibility into whether the recent default and margin trends are expected to persist or resolve.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Liquidity and repayment stress on short-term obligations, as evidenced by the ₹1.56 crore loan default to two public sector banks. 2. Declining profitability and margins, with net profit and EPS down significantly year-on-year and quarter-on-quarter. 3. Lack of strategic updates or growth initiatives, suggesting stagnation in core operations. 4. Regulatory scrutiny risk due to default disclosure, which may affect lender confidence and supplier relationships.

📋 Recent Filings

🧠 Analyst's Read

Mangalam Drugs and Organics is navigating a critical inflection point with deteriorating financial performance and an acknowledged loan default. Without clearer signs of operational recovery or financial restructuring, the company remains exposed to execution and solvency risks. Investors should monitor upcoming disclosures for signs of resolution to the default, improvement in margins, or new growth initiatives.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on MANGALAM

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when MANGALAM files new disclosures

Track MANGALAM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANGALAM — Free

Free account · 2 AI queries/day